Cremona

Italy

58 total trials 31 recruiting

Filter these 58 trials by phase, condition, sponsor and more.

Open in Search →

A Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small C … Ended recruitment

2023-507500-31-00 10 2017-08-22 Advanced or metastatic Non-small cell lung cancer (NSCLC)
Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer after FDG-PET response-adapted strategy. The PHERGain study Ended recruitment

2023-509923-42-00 4 2017-07-06 HER2- positive breast cancer
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study Ended recruitment

2023-510298-33-00 4 2016-11-29 Prostate Cancer
An international study to evaluate the safety and effectiveness of enzalutamide plus leuprolide, enzalutamide alone, and leuprolide alone in … Ended recruitment

2024-513521-23-00 5 2015-08-19 Prostate Cancer
Use of circulating tumor dna test to intensify post-operative treatment of patients with resected colon cancer. Halted

2024-515152-20-00 4 2023-03-02 Stage III and high-risk stage II resected colon cancer patients.
Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102) Ended

2023-505458-16-00 5 2022-09-13 Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpressio
Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Ended

2024-514570-43-00 5 2022-01-24 Renal cell carcinoma
A phase 2, multicenter, randomized, double blind, active controlled, parallel group study assessing the analgesic effect and safety of two d … Ended

2024-513940-27-00 4 2021-11-19 Chronic low back pain
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects with Gastrointestinal, Pancreatic, or Colorectal Cancer Ended

2023-507148-35-00 5 2019-10-03 Chemotherapy-induced Thrombocytopenia in Adult Subjects with Gastroint
Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab (A-Brave) Ended

2024-514515-10-00 5 2016-06-16 Breast Cancer

Showing 49–58 of 58 trials